JP2018522040A - 増強された再構成能および寿命を有するｔ細胞の動員および使用のための方法 - Google Patents

増強された再構成能および寿命を有するｔ細胞の動員および使用のための方法 Download PDF

Info

Publication number
JP2018522040A
JP2018522040A JP2018505461A JP2018505461A JP2018522040A JP 2018522040 A JP2018522040 A JP 2018522040A JP 2018505461 A JP2018505461 A JP 2018505461A JP 2018505461 A JP2018505461 A JP 2018505461A JP 2018522040 A JP2018522040 A JP 2018522040A
Authority
JP
Japan
Prior art keywords
cells
cell
csf
cd62l high
cd62l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018505461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522040A5 (enExample
Inventor
レイチェル ケー． キング，
レイチェル ケー． キング，
ジョン エル． マグナニ，
ジョン エル． マグナニ，
イングリッド ジー． ウィンクラー，
イングリッド ジー． ウィンクラー，
Original Assignee
グリコミメティクス， インコーポレイテッド
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド, グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2018522040A publication Critical patent/JP2018522040A/ja
Publication of JP2018522040A5 publication Critical patent/JP2018522040A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018505461A 2015-08-03 2016-08-02 増強された再構成能および寿命を有するｔ細胞の動員および使用のための方法 Pending JP2018522040A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200628P 2015-08-03 2015-08-03
US62/200,628 2015-08-03
PCT/US2016/045139 WO2017023918A1 (en) 2015-08-03 2016-08-02 Methods for the mobilization and use of t-cells with enhanced reconstitution potential and life-span

Publications (2)

Publication Number Publication Date
JP2018522040A true JP2018522040A (ja) 2018-08-09
JP2018522040A5 JP2018522040A5 (enExample) 2019-09-12

Family

ID=57943984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505461A Pending JP2018522040A (ja) 2015-08-03 2016-08-02 増強された再構成能および寿命を有するｔ細胞の動員および使用のための方法

Country Status (4)

Country Link
US (1) US20180228871A1 (enExample)
EP (1) EP3331539A4 (enExample)
JP (1) JP2018522040A (enExample)
WO (1) WO2017023918A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081585B1 (ko) * 2019-05-16 2020-02-26 (주)녹십자셀 활성화 림프구 및 이의 제조 방법

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
WO2018169853A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (ja) * 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
EP3761994A1 (en) * 2018-03-05 2021-01-13 GlycoMimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US20210290676A1 (en) * 2018-07-30 2021-09-23 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CN111789868B (zh) * 2019-04-08 2022-07-19 深圳宾德生物技术有限公司 青蒿素类化合物在促进嵌合抗原受体t细胞治疗中的应用及药物组合物
WO2021011435A1 (en) * 2019-07-12 2021-01-21 Magnani John L Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
WO2021022132A1 (en) * 2019-07-31 2021-02-04 Magnani John L Use of e-selectin antagonists to enhance the survival of reconstituted, bone marrow-depleted hosts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAKOUB-AGHA, I. ET AL., EXP HEMATOL, vol. 35, JPN6020032000, 2007, pages 861 - 71, ISSN: 0004333338 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081585B1 (ko) * 2019-05-16 2020-02-26 (주)녹십자셀 활성화 림프구 및 이의 제조 방법

Also Published As

Publication number Publication date
US20180228871A1 (en) 2018-08-16
EP3331539A1 (en) 2018-06-13
WO2017023918A1 (en) 2017-02-09
EP3331539A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
JP2018522040A (ja) 増強された再構成能および寿命を有するｔ細胞の動員および使用のための方法
AU2020244585B2 (en) Selective expansion of different subpopulations of T cells by the alteration of cell surfacing signals and signal ratio
JP7450892B2 (ja) Ｎｋ細胞のための人工ｈｌａ陽性フィーダー細胞株及びその使用
US20250223333A1 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
US8383099B2 (en) Adoptive cell therapy with young T cells
Hus et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+ CD25+ FoxP3+ regulatory T cells toward an antileukemia response
JP6543375B1 (ja) ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
US11597911B2 (en) Expansion of populations of T cells by the use of modified serum free media
US20180161366A1 (en) Methods of obtaining mononuclear blood cells and uses thereof
US20250235482A1 (en) Production and therapeutic use of off-the-shelf double negative t cells
JP7681908B2 (ja) Ｃｃｒ２＋造血幹細胞は養子細胞療法におけるｔ細胞活性化を媒介する
US20240398695A1 (en) Methods of T Cell Expansion and Activation
JP2025523068A (ja) Ｔ細胞集団を増殖させるための方法
Bao et al. Current status of leukemia cytotherapy-exploitation with immune cells
Harrison et al. Immunotherapy of multiple myeloma: the start of a long and tortuous journey
US20180078650A1 (en) Compositions and methods of treating acute myeloid leukemia
AU2016243194A1 (en) Compositions and methods of treating acute myeloid leukemia
KR102032384B1 (ko) 제대혈 단핵세포에서의 자연살해세포의 제조 방법
WO2025067472A1 (en) Methods of culturing gamma delta t cells
Singh et al. Natural killer cell-based Immunotherapy for Solid tumors: A Comprehensive Review
Kumar Singh et al. Natural killer cell-based Immunotherapy for Solid tumors: A Comprehensive Review Iran J Blood Cancer. 2025 June 30; 17 (2): 83-98
MAMACHE Cell and gene therapy Master 2 option immunology
Zanon Stem cell-like properties of memory T cells in human immune reconstitution
Dylan et al. Optimization of T-cell receptor–modified T cells for cancer
Pdldczi Immunophenotyping in Hematopoietic Stem Cell Transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210427